Brands & Strategies: Multiple Sclerosis

Table of Contents

Table of Contents

Table of Exhibits

Executive Summary

Section 1: Multiple Sclerosis Patient Populations

• Background
• Multiple Sclerosis Prevalence and Diagnosis
• US
• Europe
• Japan

Section 2: Multiple Sclerosis Treatment Overview

• Major Competitors
• Exisiting Treatments
  • Recombinant Interferon-β
  • Altered Peptide Ligands
  • Chemotherapeutics
  • Monoclonal Antibodies
  • Corticosteroids
  • Immunosuppressants

Section 3: Major Markets for Multiple Sclerosis Treatment

• Market Overview
  • MS Drug Sales by Region
  • MS Drug Sales by Class
• Market Forecast
  • Key Events
  • Drug Pricing
  • Formulary Placement
  • Recombinant Interferon-β Market
  • Altered Peptide Ligand Market
  • Chemotherapeutic Market
  • Monoclonal Antibody Market
  • Corticosteroid Market
  • Immunosuppressant Market

Section 4: Competitive Analysis

• Overview
• Competitive Landscape
  • MS Market by Competitor
  • Promotional Spending

Biogen Idec

• Product Portfolio
• Strategic Positioning
• Avonex
  • Approval History
  • Sales and Market Position
  • Avonex Competitive Analysis
  • Promotional Spending
  • Life Cycle Management
• Tysabri
  • Approval History
  • Sales and Market Position
  • Tysabri Competitive Analysis
  • Promotional Spending
  • Life Cycle Management
• Biogen Idec MS Pipeline
  • Daclizumab
  • Rituximab
  • BG-12
  • Pegylated Inferferon-β-1a
  • LINGO-1 Inhibitor

Teva Pharmaceuticals

• Product Portfolio
• Strategic Positioning
• Copaxone
  • Approval History
  • Sales and Market Position
  • Copaxone Competitive Analysis
  • Promotional Spending
  • Life Cycle Management
• Teva Pharmaceuticals MS Pipeline
  • Laquinimod
  • TV-5010
  • Oral Copaxone

Serono SA

• Product Portfolio
• Strategic Positioning
• Rebif
  • Approval History
  • Sales and Market Position
  • Rebif Competitive Analysis
  • Promotional Spending
  • Life Cycle Management
• Novantrone
  • Approval History
  • Sales and Market Position
  • Novantrone Competitive Analysis
  • Promotional Spending
  • Life Cycle Management
• Serono MS Product Pipeline
  • Oral Cladribine
  • MMP-12 Inhibitor
  • JNK Inhibitor
  • Interferon-β:Fc
  • Osteopontin

Schering AG

• Product Portfolio
• Strategic Position
• Betaseron
  • Approval History
  • Sales and Market Position
  • Betaseron Competitive Analysis
  • Promotional Spending
  • Life Cycle Management
• Schering AG MS Pipeline
  • Alemtuzumab

Section 5: Supplementary Market Analysis

Acronyms and Initialisms

Methodology

• Epidemiological Forecast Methodology
• Market Forecast Methodology
• Competitive Analysis Methodology

Table of Exhibits

Executive Summary

• Exhibit ES-1: MS Market Value, Major Markets, 2005-2010
• Exhibit ES-2: MS Market by Competitor, 2005 and 2010

Section 1: Multiple Sclerosis Patient Populations

• Prevalent and Diagnosed MS Cases (Thousands), Major Markets, 2005-2010
• Prevalent and Diagnosed MS Cases (Thousands), US, 2005-2010
• Total Prevalent Cases of MS (Thousands), by Country, Europe, 2005-2010
• Prevalent and Diagnosed MS Cases, Japan, 2005-2010

Section 2: Multiple Sclerosis Treatment Overview

• Exhibit 2-1: MS Drugs, by Major Competitor
• Exhibit 2-2: MS Drugs, by Drug Class

Section 3: Major Markets for Multiple Sclerosis Treatment

• Exhibit 3-1: MS Market ($US), Major Markets, 2005-2010 (Graphical Format)
• Exhibit 3-2: MS Market ($US), Major Markets, 2005-2010 (Tabular Format)
• Exhibit 3-3: MS Market ($US), by Country, 2005-2010
• Exhibit 3-4: MS Market, by Country as a % of Total, 2005 and 2010
• Exhibit 3-5: MS Market ($US), by Drug Class, 2005-2010
• Exhibit 3-6: Key Events , MS Market, 2005-2010
• Exhibit 3-7: Price to Treat per Day ($US), Recombinant Interferon-β, 2005-2010
• Exhibit 3-8: Recombinant Interferon-β Pricing ($US), Brand vs. Generic Price, 2005
• Exhibit 3-9: Price to Treat per Day ($US), Altered Peptide Ligands, 2005-2010
• Exhibit 3-10: Price to Treat per Day ($US), Chemotherapeutics, 2005-2010
• Exhibit 3-11: Chemotherapeutic Pricing ($US), Brand vs. Generic Price, 2005
• Exhibit 3-12: Price to Treat per Day ($US), Monoclonal Antibodies, 2005-2010
• Exhibit 3-13: Price to Treat per Day ($US), Corticosteroids, 2005-2010
• Exhibit 3-14: Corticosteroid Pricing ($US), Brand vs. Generic Price, 2005
• Exhibit 3-15: Price to Treat per Day ($US), Immunosuppressants, 2005-2010
• Exhibit 3-16: Immunosuppressant Pricing ($US), Brand vs. Generic Price, 2005
• Exhibit 3-17: US Formulary Placement of MS-Indicated Therapies
• Exhibit 3-18: Recombinant Interferon-β Market ($US), 2005-2010
• Exhibit 3-19: Recombinant Interferon-β Market ($US), by Country, 2005-2010
• Exhibit 3-20: Recombinant Interferon-β Market ($US), by Drug, 2005-2010
• Exhibit 3-21: Recombinant Interferon-β Branded Market Share, by Brand and Country, 2005 and 2010
• Exhibit 3-22: Altered Peptide Ligand Market ($US), 2005-2010
• Exhibit 3-23: Altered Peptide Ligand Market ($US), by Country, 2005-2010
• Exhibit 3-24: Chemotherapeutics Market ($US), 2005-2010
• Exhibit 3-25: Chemotherapeutics Market ($US), by Country, 2005-2010
• Exhibit 3-26: Chemotherapeutics Market ($US), by Drug, 2005-2010
• Exhibit 3-27: Monoclonal Antibody Market ($US), 2005-2010
• Exhibit 3-28: Monoclonal Antibody Market ($US), by Country, 2005-2010
• Exhibit 3-29: Monoclonal Antibody Market ($US), by Drug, 2005-2010
• Exhibit 3-30: Corticosteroid Market ($US), 2005-2010
• Exhibit 3-31: Corticosteroid Market ($US), by Country, 2005-2010
• Exhibit 3-32: Corticosteroid Market ($US), by Drug, 2005-2010
• Exhibit 3-33: Immunosuppressant Market ($US), 2005-2010
• Exhibit 3-34: Immunosuppressant Market ($US), by Country, 2005-2010
• Exhibit 3-35: Imuran Market ($US) by Drug, 2005-2010

Section 4: Competitive Analysis

• Exhibit 4-1: MS Market Competitive Position, 2005 and 2010
• Exhibit 4-2: MS Market ($US), by Company, 2005-2010
• Exhibit 4-3: Promotional Spend for MS Therapies, by Company, 2005
• Exhibit 4-4: Promotional Spending Among First-Line MS Therapies, 2005
• Exhibit 4-5: Summary of Biogen Idec' s MS Product Portfolio
• Exhibit 4-6: Biogen Idec MS Revenues ($US), by Brand, 2005-2010
• Exhibit 4-7: Timeline of Avonex Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-8: Key Clinical Trials Supporting Avonex' Regulatory Approvals
• Exhibit 4-9: Timeline of Tysabri Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-10: Key Clinical Trials Supporting Tysabri' s Regulatory Approvals
• Exhibit 4-11: Summary of Teva Pharmaceuticals MS Product Portfolio
• Exhibit 4-12: Timeline of Copaxone Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-13: Key Clinical Trials Supporting Copaxone' s Regulatory Approvals
• Exhibit 4-14: Summary of Serono SA' s MS Product Portfolio
• Exhibit 4-15: Timeline of Rebif Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-16: Key Clinical Trials Supporting Rebif' s Regulatory Approvals
• Exhibit 4-17: Key Clinical Trials Supporting Novantrone' s Regulatory Approvals
• Exhibit 4-18: Summary of Schering AG' s MS Product Portfolio
• Exhibit 4-19: Timeline of Betaseron Regulatory Approvals in the Seven Major Pharmaceutical Markets
• Exhibit 4-20: Key Clinical Trials Supporting Betaseron' s Regulatory Approvals
• Exhibit 4-21: Key Clinical Trials Supporting Betaseron' s Regulatory Approvals, Continued

Section 5: Supplementary Market Analysis

• Exhibit 5-1: Total Interferon-β-1a (IM) Market ($US), by Country, 2005-2010
• Exhibit 5-2: Avonex Market ($US), by Country, 2005-2010
• Exhibit 5-3: Total Interferon-β-1a (SC) Market ($US), by Country, 2005-2010
• Exhibit 5-4: Rebif Market ($US), by Country, 2005-2010
• Exhibit 5-5: Total Interferon-β-1b Market ($US), by Country, 2005-2010
• Exhibit 5-6: Betaseron Market ($US), by Country, 2005-2010
• Exhibit 5-7: Total Mitoxantrone Market ($US), by Country, 2005-2010
• Exhibit 5-8: Novantrone Market ($US), by Country, 2005-2010
• Exhibit 5-9: Total Cyclophosphamide Market ($US), by Country, 2005-2010
• Exhibit 5-10: Cytoxan Market ($US), by Country, 2005-2010
• Exhibit 5-11: Total Methotrexate Market ($US), by Country, 2005-2010
• Exhibit 5-12: Rheumatrex Market ($US), by Country, 2005-2010
• Exhibit 5-13: Methylprednisolone Market ($US), by Drug, 2005-2010
• Exhibit 5-14: Solu-Medrol Market ($US), by Country, 2005-2010
• Exhibit 5-15: Total Prednisone Market ($US), by Country, 2005-2010
• Exhibit 5-16: Deltasone Market ($US), by Country, 2005-2010
• Exhibit 5-17: Total Azathioprine Market ($US), by Country, 2005-2010
• Exhibit 5-18: Imuran Market ($US), by Country, 2005-2010